Pyrantel
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Pyrantel
Pyrantel: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Pyrantel, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| ascaridiasis |
| enterobiasis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 3047J | Anthel 125 | Tablet 125 mg (as embonate) | Valid |
Cytotoxicity
Not applicable. Pyrantel is not an antineoplastic drug.
Safety Considerations
- Knowledge-graph contraindication signals: liver disease and gallbladder disease (derived from drug-disease graph edges, not from label text; verify against the Product Information).
- Drug Interactions (2 moderate, from DDInter):
- Iodide I-131 (Moderate)
- Iodide I-123 (Moderate)
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.